ScreenerHero

ATRAAtara Biotherapeutics, Inc.

NAS · US · Healthcare · Biotechnology · atarabio.com
9.700USD+1.04%Mkt Cap: 97.37M $P/E: —

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleuce…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap97.37M $
Enterprise Value94.16M $
Revenue (TTM)6.19M $
Gross Profit99.56M $
Net Income (TTM)32.69M $
Revenue/Share0.4400 USD
Last Price9.700 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0465131078
Valuation
P/E (Trailing)—
P/E (Forward)8.45
PEG—
EV/EBITDA-8.52
EV/Revenue15.20
P/S15.20
P/B-2.39
EPS (TTM)-1.51
EPS (Forward)1.11
52W Range
3.92038% of range19.14
52W High19.14 USD
52W Low3.920 USD
Profitability
Gross Margin82.44%
Oper. Margin-627.46%
EBITDA Margin-178.53%
Profit Margin27.07%
ROE-84.90%
ROA161.54%
Growth
Revenue Growth-96.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.94M $
CapEx (TTM)—
FCF Margin-202.17%
FCF Yield-12.86%
Net Debt6.00K $
Net Debt/EBITDA-0.00
Balance Sheet
Debt/Equity-0.27
Current Ratio1.98
Quick Ratio1.49
Book Value/Sh-3.9180 USD
Cash/Share0.9840 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJun 20, 2024
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.67 USD
Upside (mean)+40.9%
Target Range10.00 USD – 18.00 USD
$10.00+40.9% to mean$18.00
# Analysts3
Ownership
Shares Out.10.04M
Float4.73M
Insiders15.19%
Institutions57.67%
Short Interest
Short Ratio7.1d
Short % Float8.49%
Short % Out.5.96%
Shares Short536.90K
Short (prev mo.)361.52K
Technical
SMA 509.297 (+4.3%)
SMA 2008.991 (+7.9%)
Beta0.10
S&P 52W Chg18.16%
Avg Vol (30d)64.16K
Avg Vol (10d)58.30K
Technical Indicators
RSI (14)59.3
MACD0.0194
MACD Signal-0.1488
MACD Hist.+0.1681
BB Upper9.575 USD
BB Middle8.490 USD
BB Lower7.404 USD
BB Width25.57%
ATR (14)0.7269 USD
Vol Ratio (20d)0.47x